Tenascin C (TNC)
| Code | Size | Price |
|---|
| TEN001 | 1 ml | £534.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: T2H5
Regulatory Status: RUO
Target Species: Human
Applications:
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Storage:
2-8°C
Documents
Further Information
Applications Description:
IHC(C,P), WB
Background:
The antibody (T2H5) reacts with at least two forms of Tenascin (apparent MW between 210 and 300 kDa), an. During embryonic development Tenascin appears to play a regulatory role in epithelial differentiation. In many mature tissues Tenascin disappears, but reappears in tissue regeneration and repair, as well as in neoplasia. Tenascin expression has been noted in a variety of epithelial neoplasms, including skin-, prostate-, breast- and colon cancer. Tenascin is a high molecular ECM glycoprotein (calculated MW 240 kDa), which contains hexamere repeat-rich single chains. It contains EGF-, Fibronectin III- and Fibronectin-similar structures. During organogenesis it is exprimed temporarily by many organs. During adulthood expression of the protein it reappears only in regeneration, wound healing and in stroma of various tumours. Probably it has an anti-adhesive function, which plays a role during tumour spreading. Tenascin is found in the central and peripheral nerve system, in smooth muscle, tendon and hyper-proliferative skin. Human Tenascin, extracellular matrix protein.
Caution:
*These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.
** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!
** The preservative sodium azide is known to be poisonous and potentially hazardous to health. It should be handled only by trained staff. Despite of the product's low azide concentration it must be handled with care. Dispose according to regional rules!
Concentration:
50 ?g/ml
Immunogen:
Purified Tenascin derived from mammary tumour cells
Incubation Time:
60 min at RT
Positive Control:
Colon carcinoma, abortive tissue, hyperproliferative skin, tonsil
Pre-Treatment:
Unmasking methods for paraffin sections are not established
Product:
Purified antibody in phosphate buffer, BSA and 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 ?l working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Purification Method:
Purified antibody in phosphate buffer, BSA and 0.09 % sodium azide**. The volume is sufficient for at least 100 immunohistochemical tests (100 ?l working solution / test). Use appropriate antibody diluent e.g. BIOLOGO Art .No. PU002.
Secondary Reagents:
We recommend the use of BIOLOGO's Universal Staining System DAB (Art. No. DA005) or AEC (Art.-No. AE005).
Species Reactivity:
Human
UniProt:
P24821
Working Concentration:
(liquid conc.) 1:10-1:50
References
1. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Tenascin is overexpressed in vitiligo lesional skin and inhibits melanocyte adhesion. Br J Dermatol. 1997 Aug;137(2):171-8.
2. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996 Apr;148(4):1219-28.
3. Rulo HF, van Vlijmen-Willems IM, Schalkwijk J, Verstraeten AA, van de Kerkhof PC. Normal human skin demonstrates marked site-variation of tenascin expression, not correlated to epidermal proliferation (Ki-67 binding).J Dermatol Sci. 1993 Feb;5(1):54-7.
4. Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, De Jongh GJ, Schalkwijk J. Tenascin expression in basal cell carcinoma. Br J Dermatol. 1992 Dec;127(6):571-4.
5.. M?ller S., Neureiter D., Stolte M. et al. (1991) Virchows Arch. 438; 435-441.
2. Le Poole IC, van den Wijngaard RM, Westerhof W, Das PK. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol. 1996 Apr;148(4):1219-28.
3. Rulo HF, van Vlijmen-Willems IM, Schalkwijk J, Verstraeten AA, van de Kerkhof PC. Normal human skin demonstrates marked site-variation of tenascin expression, not correlated to epidermal proliferation (Ki-67 binding).J Dermatol Sci. 1993 Feb;5(1):54-7.
4. Verstraeten AA, Mackie EJ, Hageman PC, Hilgers J, Schol DJ, De Jongh GJ, Schalkwijk J. Tenascin expression in basal cell carcinoma. Br J Dermatol. 1992 Dec;127(6):571-4.
5.. M?ller S., Neureiter D., Stolte M. et al. (1991) Virchows Arch. 438; 435-441.